Literature DB >> 1840294

Leukosialin, a major O-glycan-containing sialoglycoprotein defining leukocyte differentiation and malignancy.

M Fukuda1.   

Abstract

Leukosialin, also called CD43 or sialophorin, is a major sialoglycoprotein expressed widely in various leukocytes (granulocytes, monocytes/macrophages and T-lymphocytes). Leukosialin is heavily glycosylated by O-linked oligosaccharides (70-80 oligosaccharides/molecule) and the structures of those O-glycans are characteristic to each cell lineage and differentiation stage. In particular, the branched hexasaccharide, NeuNAc alpha 2----3Gal beta 1----3(NeuNAc alpha 2----3Gal beta 1----4GlcNAc beta 1----6)GalNAc is specifically expressed in activated T-lymphocytes as well as in thymocytes and T-lymphocytes from patients with leukaemia, and immuno-deficiency syndromes. A portion of these O-glycans are attached to a domain with tandem repeats in the polypeptide of leukosialin. However, the entire translation product, including such tandem repeats, is coded by one exon and a short novel promoter sequence confers the expression of the leukosialin gene. Leukosialin is apparently involved in T-cell-B-cell interaction during immune reaction and binds to ligands on antigen-presenting B-cells. These results imply that leukosialin plays critical roles in immune cell interaction and differences in attached O-glycans most likely influence the interaction of leukosialin with ligands.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1840294     DOI: 10.1093/glycob/1.4.347

Source DB:  PubMed          Journal:  Glycobiology        ISSN: 0959-6658            Impact factor:   4.313


  32 in total

1.  Differentiation-dependent glycosylation of gp190, an oncofetal crypt cell antigen expressed by Caco-2 cells.

Authors:  N Malagolini; D Cavallone; F Serafini-Cessi
Journal:  Glycoconj J       Date:  2000-05       Impact factor: 2.916

Review 2.  T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival.

Authors:  Mary C Clark; Linda G Baum
Journal:  Ann N Y Acad Sci       Date:  2012-01-30       Impact factor: 5.691

3.  Protein glycosylation in cancer biology: an overview.

Authors:  F Dall'olio
Journal:  Clin Mol Pathol       Date:  1996-06

4.  O-GLYCBASE version 2.0: a revised database of O-glycosylated proteins.

Authors:  J E Hansen; O Lund; K Rapacki; S Brunak
Journal:  Nucleic Acids Res       Date:  1997-01-01       Impact factor: 16.971

5.  Processing O-glycan core 1, Gal beta 1-3GalNAc alpha-R. Specificities of core 2, UDP-GlcNAc: Gal beta 1-3 GalNAc-R(GlcNAc to GalNAc) beta 6-N-acetylglucosaminyltransferase and CMP-sialic acid: Gal beta 1-3GalNAc-R alpha 3-sialyltransferase.

Authors:  W Kuhns; V Rutz; H Paulsen; K L Matta; M A Baker; M Barner; M Granovsky; I Brockhausen
Journal:  Glycoconj J       Date:  1993-10       Impact factor: 2.916

6.  Methyl-CpG-binding protein MeCP2 represses Sp1-activated transcription of the human leukosialin gene when the promoter is methylated.

Authors:  S Kudo
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

7.  Persistent repression of a functional allele can be responsible for galactosyltransferase deficiency in Tn syndrome.

Authors:  M Thurnher; S Rusconi; E G Berger
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

Review 8.  Will the transgenic mouse serve as a Rosetta Stone to glycoconjugate function?

Authors:  J D Marth
Journal:  Glycoconj J       Date:  1994-02       Impact factor: 2.916

9.  Binding of the Streptococcus gordonii DL1 surface protein Hsa to the host cell membrane glycoproteins CD11b, CD43, and CD50.

Authors:  Yumiko Urano-Tashiro; Ayako Yajima; Eizo Takashima; Yukihiro Takahashi; Kiyoshi Konishi
Journal:  Infect Immun       Date:  2008-08-04       Impact factor: 3.441

10.  Glycogene expression alterations associated with pancreatic cancer epithelial-mesenchymal transition in complementary model systems.

Authors:  Kevin A Maupin; Arkadeep Sinha; Emily Eugster; Jeremy Miller; Julianna Ross; Vincent Paulino; Venkateshwar G Keshamouni; Nhan Tran; Michael Berens; Craig Webb; Brian B Haab
Journal:  PLoS One       Date:  2010-09-27       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.